NHS Trusts Operating on Fewer Patients with Palantir FDP, Warns Foxglove

Why It Matters

If the FDP does not reliably increase throughput, the multi‑hundred‑million‑dollar investment may not deliver expected efficiency gains, prompting scrutiny of public‑sector tech spending. The findings also expose a transparency gap that hampers parliamentary oversight of digital health initiatives.

Key Takeaways

• 30% of trusts using Palantir FDP saw fewer surgeries
• 13 trusts performed 9,073 fewer operations after adoption
• NHS contract with Palantir exceeds £300 million (~$380 million)
• Foxglove says data transparency lacking; comparative data not released
• NHS officials argue benefits limited to well‑adopted trusts, results long‑term

Pulse Analysis

Palantir’s entry into the UK health system has been framed as a digital transformation milestone, with the government signing a contract worth more than £300 million (about $380 million) to deploy its Federated Data Platform across NHS trusts. The platform promises to centralise patient data, streamline scheduling and ultimately increase surgical capacity. Early optimism was bolstered by public statements that the FDP would lift overall operation counts, positioning Palantir as a strategic partner for a strained public service.

However, the recent Foxglove investigation, based on Freedom‑of‑Information requests, paints a more nuanced picture. Of the 41 trusts using the Inpatient CCS module, 13 reported a net loss of 9,073 operations after implementation, equating to roughly 30% of adopters delivering fewer procedures than before. This discrepancy challenges the narrative of uniform efficiency gains and highlights the difficulty of measuring impact without baseline data from non‑adopting trusts. Critics argue that aggregating positive outcomes while obscuring negative ones undermines accountability and makes it harder for policymakers to assess true return on investment.

The episode underscores broader concerns about public‑sector procurement of high‑cost technology. Transparency gaps, as highlighted by Foxglove, limit parliamentary scrutiny and may erode public trust in large‑scale digital contracts. Moreover, NHS officials caution that benefits may be realised only in trusts that fully integrate the platform and develop clinician‑led use cases, a process that could take years. As governments worldwide grapple with balancing innovation against fiscal responsibility, the Palantir‑NHS case serves as a cautionary tale about the need for rigorous, data‑driven evaluation before committing billions to unproven tech solutions.